93 related articles for article (PubMed ID: 10973767)
1. Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study.
Ronner E; van Kesteren HA; Zijnen P; Altmann E; Molhoek PG; van der Wieken LR; Cuffie-Jackson CA; Neuhaus KL; Simoons ML
Eur Heart J; 2000 Sep; 21(18):1530-6. PubMed ID: 10973767
[TBL] [Abstract][Full Text] [Related]
2. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.
Giugliano RP; Roe MT; Harrington RA; Gibson CM; Zeymer U; Van de Werf F; Baran KW; Hobbach HP; Woodlief LH; Hannan KL; Greenberg S; Miller J; Kitt MM; Strony J; McCabe CH; Braunwald E; Califf RM;
J Am Coll Cardiol; 2003 Apr; 41(8):1251-60. PubMed ID: 12706917
[TBL] [Abstract][Full Text] [Related]
3. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ
J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073
[TBL] [Abstract][Full Text] [Related]
4. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
Ohman EM; Kleiman NS; Gacioch G; Worley SJ; Navetta FI; Talley JD; Anderson HV; Ellis SG; Cohen MD; Spriggs D; Miller M; Kereiakes D; Yakubov S; Kitt MM; Sigmon KN; Califf RM; Krucoff MW; Topol EJ
Circulation; 1997 Feb; 95(4):846-54. PubMed ID: 9054741
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.
Kaul U; Gupta RK; Haridas KK; Ramesh SS; Sethi KK; Singh B; Agarwal R; Yadave RD; Ghose T; Sapra RR; Bajaj R; Shahi M; Bhagwat A; Kumar P; Mathews OP; Soni PK;
Catheter Cardiovasc Interv; 2002 Dec; 57(4):497-503. PubMed ID: 12455085
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.
Kleiman NS; Tracy RP; Talley JD; Sigmon K; Joseph D; Topol EJ; Califf RM; Kitt M; Ohman EM
J Thromb Thrombolysis; 2000 Jan; 9(1):5-12. PubMed ID: 10590183
[TBL] [Abstract][Full Text] [Related]
7. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.
Gibson CM; Jennings LK; Murphy SA; Lorenz DP; Giugliano RP; Harrington RA; Cholera S; Krishnan R; Califf RM; Braunwald E;
Circulation; 2004 Aug; 110(6):679-84. PubMed ID: 15262838
[TBL] [Abstract][Full Text] [Related]
8. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction.
Roe MT; Green CL; Giugliano RP; Gibson CM; Baran K; Greenberg M; Palmeri ST; Crater S; Trollinger K; Hannan K; Harrington RA; Krucoff MW;
J Am Coll Cardiol; 2004 Feb; 43(4):549-56. PubMed ID: 14975462
[TBL] [Abstract][Full Text] [Related]
9. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
Pancioli AM; Broderick J; Brott T; Tomsick T; Khoury J; Bean J; del Zoppo G; Kleindorfer D; Woo D; Khatri P; Castaldo J; Frey J; Gebel J; Kasner S; Kidwell C; Kwiatkowski T; Libman R; Mackenzie R; Scott P; Starkman S; Thurman RJ;
Stroke; 2008 Dec; 39(12):3268-76. PubMed ID: 18772447
[TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
11. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
[TBL] [Abstract][Full Text] [Related]
12. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction.
Pinto DS; Kirtane AJ; Ruocco NA; Deibele AJ; Shui A; Buros J; Murphy SA; Gibson CM
Am J Cardiol; 2005 Dec; 96(11):1494-7. PubMed ID: 16310428
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
Peters RJ; Spickler W; Théroux P; White H; Gibson M; Molhoek PG; Anderson HV; Weitz JI; Hirsh J; Weaver WD
Am Heart J; 2001 Aug; 142(2):237-43. PubMed ID: 11479461
[TBL] [Abstract][Full Text] [Related]
14. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.
J Am Coll Cardiol; 1998 Dec; 32(7):2003-10. PubMed ID: 9857885
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
[TBL] [Abstract][Full Text] [Related]
16. Patency, perfusion, performance--the desirable triplets of combination thrombolytic therapy.
Wilcox R
Eur Heart J; 2000 Sep; 21(18):1495-7. PubMed ID: 10973761
[No Abstract] [Full Text] [Related]
17. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
[TBL] [Abstract][Full Text] [Related]
18. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
[TBL] [Abstract][Full Text] [Related]
19. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.
Tcheng JE; Harrington RA; Kottke-Marchant K; Kleiman NS; Ellis SG; Kereiakes DJ; Mick MJ; Navetta FI; Smith JE; Worley SJ
Circulation; 1995 Apr; 91(8):2151-7. PubMed ID: 7697843
[TBL] [Abstract][Full Text] [Related]
20. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Peterson JG; Topol EJ; Roe MT; Sapp SK; Lincoff AM; Deckers JW; Blackstone EH; Harrington RA; Califf RM; Lauer MS
Am J Cardiol; 2001 Mar; 87(5):532-6. PubMed ID: 11230834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
